What is SiriusXT?
SiriusXT is a trailblazer in soft X-ray microscopy, developing the SXT-100, the first commercially available laboratory-scale soft X-ray microscope. This innovative technology is designed for sophisticated cellular imaging, providing researchers with label-free, near-native state insights into cellular changes and drug responses. By enabling high-resolution 3D imaging of entire cells and tissues, SiriusXT's platform is poised to accelerate breakthroughs in biomedical research, particularly in disease and drug discovery. The company's mission, originating from expertise at University College Dublin, is to democratize high-resolution imaging for life science laboratories, thereby speeding up the development of critical therapies.
How much funding has SiriusXT raised?
SiriusXT has raised a total of $3.3M across 1 funding round:
Unspecified
$3.3M
Unspecified (2016): $3.3M, investors not publicly disclosed
What's next for SiriusXT?
The substantial enterprise-level backing positions SiriusXT for significant scaling and further technological advancement. With a focus on making advanced imaging accessible, the company is likely to invest in expanding its commercial reach, enhancing the capabilities of the SXT-100, and potentially developing next-generation imaging solutions. This strategic capital infusion will be crucial for solidifying its market presence and driving innovation in the competitive field of biomedical research tools, ultimately aiming to expedite the creation of life-saving treatments.
See full SiriusXT company page
